NCT04592835
Phase 1 to assess safety, tolerability, PK
|
24 healthy volunteers
|
DWRX2003 (niclosamide i.m.) vs placebo
single ascending dose study
|
i.m.
|
Daewoong Pharmaceutical Co
|
Not yet recruiting
|
NCT04524052
Phase 1 to assess safety, tolerability, PK/PD
|
32 healthy volunteers
|
DWRX2003 (niclosamide i.m. depot) vs placebo
|
i.m.
|
Daewoong Pharmaceutical Co
|
Not yet recruiting
|
NCT04749173
Phase 1 safety, tolerability and PK
|
24 healthy volunteers
|
DWRX2003 (niclosamide i.m.) vs placebo
|
i.m.
|
Daewoong Pharmaceutical Co
|
Recruiting
|
NCT04541485 Phase 1 to assess safety, tolerability and PD |
40
COVID-19 patients (low-moderate risk) |
DWRX2003 (niclosamide i.m.
depot) vs placebo |
i.m. |
Daewoong Pharmaceutical Co |
Not yet
recruiting |
NCT04644705
Phase 1 to assess safety and PK
|
28 healthy volunteers
|
Niclosamide and camostat vs placebo
|
p.o, tablet and novel galenic preparation
|
Charité Research Organisation GmbH
|
Recruiting
|
EUCTR2020-002233-15-DE
Phase 2
|
40 participants with mild-moderate COVID-19
|
Niclosamide and camostat tablet vs placebo
|
p.o, tablet
|
Charité Research Organisation GmbH
|
Suspended (to pandemic situation)
|
NCT04576312
Phase 1
|
64 healthy volunteers
|
UNI911 (niclosamide inhalation + nasal spray) vs placebo
|
Solution for inhalation and intranasal application
|
UNION therapeutics
|
Completed, results published Backer et al. (2021)
|
NCT04932915 Phase 2 study to assess safety and efficacy |
330
asymptomatic or mild COVID-19 participants |
UNI91103 (niclosamide nasal
spray) vs placebo |
Solution for intranasal application |
UNION
therapeutics |
Not yet recruiting |
NCT04870333 Phase 2/3
Chemoprophylaxis trial in vulnerable patients
|
1500 participants from vulnerable patient populations
|
UNI91103 (niclosamide nasal spray) vs placebo
|
Solution for intranasal application
|
Cambridge University Hospitals NHS Foundation Trust
|
Recruiting
|
NCT04436458
Phase 2
|
100 participants with moderate COVID-19 with gastrointestinal signs
symptoms
|
Niclosamide + SoC vs placebo
|
p.o, tablet
|
First Wave Bio
|
Not yet recruiting
|
NCT04542434
Phase 2
|
148 participants with moderate COVID-19 with gastrointestinal signs
symptoms
|
Niclosamide vs placebo
|
p.o, tablet
|
First Wave Bio
|
Not yet recruiting
|
NCT04603924
Phase 2/3
|
436 participants with moderate-severe COVID-19
|
ANA001 (niclosamide capsules) vs placebo
|
p.o, capsules
|
NeuroBo Pharmaceuticals
|
Recruiting
|
NCT04558021
Phase 3
|
200 patients with moderate COVID-19
|
Novel niclosamide suspension formulation as add-on to SoC vs
placebo
|
p.o, suspension
|
Imuneks Farma ilac San
|
Recruiting
|
NCT04753619 Phase 2 open label randomized controlled trial |
150 patients with COVID-19 ranging from mild-severe |
Niclosamide add on
to standard of care |
p.o, tablet |
University of Baghdad |
Completed,
results published Abdulamir et al. (2021) |
NCT04399356
Phase 2
|
73 participants with mild-moderate COVID-19
|
Niclosamide + SoC vs placebo
|
p.o, tablet
|
Tufts Medical Center
|
Active, not recruiting
|
NCT04858425
Phase 2
|
148 participants with COVID-19 gastrointestinal infection
|
Niclosamide vs placebo
|
p.o, tablet
|
AzurRx BioPharma
|
Recruiting
|
CTRI/2020/04/024949 phase 2 |
48 participants with very mild
COVID-19 |
Niclosamide add on to standard of care |
p.o, tablet |
Lady
Hardinge Medical College |
Recruiting |
TACTIC-E/ NCT04393246
Phase 2/3
|
~469 participants with moderate-severe covid
(pre-ICU)
|
EDP1815, dapagliflozin, ambrisentan, niclosamide, SoC
|
Solution for nebulization and intranasal application
|
Cambridge University Hospitals NHS Foundation Trust
|
Recruiting
|